Quantitative Proteomics Reveal That Metabolic Improvement Contributes to the Cardioprotective Effect of T₈₉ on Isoproterenol-Induced Cardiac Injury.

ABSTRACT:

Background

T₈₉, a traditional Chinese medicine, has passed phase II, and is undergoing phase III clinical trials for treatment of ischemic cardiovascular disease by the US FDA. However, the role of T₈₉ on isoproterenol (ISO)-induced cardiac injury is unknown. The present study aimed to explore the effect and underlying mechanism of T₈₉ on ISO-induced cardiac injury.

Methods

Male Sprague-Dawley rats received subcutaneous injection of ISO saline solution at 24 h intervals for the first 3 days and then at 48 h intervals for the next 12 days. T₈₉ at dose of 111.6 and 167.4 mg/kg was administrated by gavage for 15 consecutive days. Rat survival rate, cardiac function evaluation, morphological observation, quantitative proteomics, and We

SUBMITTER: Wei XH 

PROVIDER: S-EPMC8273540 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature